Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
Top Cited Papers
- 1 July 2001
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in AIDS
- Vol. 15 (11), 1389-1398
- https://doi.org/10.1097/00002030-200107270-00008
Abstract
To identify clinical factors associated with prevalence of fat atrophy (lipoatrophy) and fat accumulation (lipoaccumulation) in HIV-1 infected patients. Evaluation of HIV-1 infected patients seen for routine care between 1 October and 31 December 1998 in the eight HIV Outpatient Study (HOPS) clinics. Eight clinics specializing in the care of HIV-1 infected patients. A total of 1077 patients were evaluated for signs of fat maldistribution. A standardized set of questions and specific clinical signs were assessed. Demographic, clinical and pharmacological data for each patient were also included in the analysis. Demographic, immunologic, virologic, clinical, laboratory, and drug treatment factors were assessed in stratified and multivariate analyses for their relationship to the presence and severity of fat accumulation and atrophy. Independent factors for moderate/severe lipoatrophy for 171 patients were increasing age, any use of stavudine, use of indinavir for longer than 2 years, body mass index (BMI) loss, and measures of duration and severity of HIV disease. Independent risk factors for moderate/severe fat accumulation for 104 patients were increasing age, BMI gain, measures of amount and duration of immune recovery, and duration of antiretroviral therapy (ART). The number of non-drug risk factors substantially increased the likelihood of lipoatrophy. If non-drug risk factors were absent, lipoatrophy was unusual regardless of the duration of drug use. HIV-associated lipodystrophy is associated with several host, disease, and drug factors. While prevalence of lipoatrophy increased with the use of stavudine and indinavir, and lipoaccumulation was associated with duration of ART, other non-drug factors were strongly associated with both fat atrophy and accumulation.Keywords
This publication has 12 references indexed in Scilit:
- A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndromeAIDS, 2000
- The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophyAIDS, 1999
- A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapyAIDS, 1999
- Changing Conditions and Treatments in a Dynamic Cohort of Ambulatory HIV PatientsAnnals of Epidemiology, 1999
- “Buffalo Humps” Associated with Protease InhibitorsAnnals of Internal Medicine, 1998
- Pseudo‐Cushing's Syndrome in Human Immunodeficiency Virus– Infected PatientsClinical Infectious Diseases, 1998
- A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitorsAIDS, 1998
- Declining Morbidity and Mortality among Patients with Advanced Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1998
- “Buffalo hump” in men with HIV-1 infectionThe Lancet, 1998
- Protease inhibitor-associated hyperglycaemiaThe Lancet, 1997